• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Rational treatment of uncontrollable, life-threatening hemorrhage with recombinant factor VIIa].

作者信息

Stensballe Jakob, Lethagen Stefan, Lippert Freddy, Johansson Pär Ingemar

机构信息

Anaetesi- og operationsklinikken 4231, H:S Rigshospitalet, DK-2100 København Ø.

出版信息

Ugeskr Laeger. 2005 Jun 20;167(25-31):2756-9.

PMID:16014259
Abstract

We present a standardised treatment algorithm used to treat life-threatening haemorrhage (LTH) due to trauma, surgery, or delivery at Rigshospitalet, Copenhagen University Hospital. Balanced transfusion therapy and infusion of fibrinogen must precede recombinant factor VIIa (rFVIIa) treatment. rFVIIa is indicated in patients with uncontrollable LTH ( > 1 blood component per 10 kg of whole body weight per hour) despite surgical treatment and adequately balanced transfusion. We recommend rFVIIa at a dose of 100 microg/kg. The dosage recommendation is not evidence-based. A thorough, prospective surveillance program to monitor the treatment's efficacy and safety is therefore mandatory. The Blood Bank services, guides and coordinates the treatment.

摘要

相似文献

1
[Rational treatment of uncontrollable, life-threatening hemorrhage with recombinant factor VIIa].
Ugeskr Laeger. 2005 Jun 20;167(25-31):2756-9.
2
[Treatment of uncontrollable, life-threatening hemorrhage].[难以控制的危及生命的出血的治疗]
Ugeskr Laeger. 2005 Jun 20;167(25-31):2789-90.
3
[Rational blood component therapy in patients with life-threatening hemorrhage].
Ugeskr Laeger. 2005 Jun 20;167(25-31):2753-5.
4
Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.重组活化凝血因子VIIa用于控制出血:非血友病患者的止血实验室研究
Blood Coagul Fibrinolysis. 2006 Jun;17(4):241-9. doi: 10.1097/01.mbc.0000224842.25592.8a.
5
Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.单中心经验:重组凝血因子VIIa在无先天性出血性疾病儿童急性危及生命出血中的应用
Pediatr Hematol Oncol. 2008 Jun;25(4):301-11. doi: 10.1080/08880010802016904.
6
A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.重组凝血因子VIIa超说明书用药的多中心评估:临床经验及相关结果
Transfusion. 2005 Sep;45(9):1434-42. doi: 10.1111/j.1537-2995.2005.00548.x.
7
Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report.使用重组活化因子VII控制一名患有血小板质量异常的幼儿出血:病例报告。
Blood Coagul Fibrinolysis. 2006 Jun;17(4):317-22. doi: 10.1097/01.mbc.0000224853.50248.6f.
8
[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group].[重组因子VIIa在内科及儿科疾病中潜在应用领域的临床评估。专家组建议]
Med Klin (Munich). 2007 Jan 15;102(1):70-81. doi: 10.1007/s00063-007-1012-9.
9
Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.重组活化凝血因子VII(rFVIIa)治疗婴儿出血症。
Paediatr Anaesth. 2006 Oct;16(10):1042-6. doi: 10.1111/j.1460-9592.2006.02039.x.
10
Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use.
Acta Obstet Gynecol Scand. 2006;85(10):1239-47. doi: 10.1080/00016340600855839.

引用本文的文献

1
Recombinant factor VIIa: hemostatic adjunct in the coagulopathic burn patient.重组凝血因子VIIa:凝血病烧伤患者的止血辅助药物。
Eplasty. 2009 Jul 1;9:e27.